Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Individuals with Barth Syndrome Chart New Path for the Review of Drugs

Barth Syndrome Foundation's recent listening session with FDA sheds light on one rare disease community's acceptance of less certainty of treatment benefits


News provided by

Barth Syndrome Foundation

Mar 17, 2021, 10:30 ET

Share this article

Share toX

Share this article

Share toX

Barth Syndrome Foundation Logo
Barth Syndrome Foundation Logo

BOSTON, March 17, 2021 /PRNewswire-PRWeb/ -- Barth Syndrome Foundation (BSF) shares initial reactions today to a historic dialogue held in a recent listening session with the U.S. Food and Drug Administration (FDA). The March 3rd, 2021 FDA listening session was requested by members of the Barth syndrome community earlier this year following submission of a global petition. The meeting was a first-of-its-kind and a significant milestone in BSF's multi-year strategic advocacy agenda that spotlights the patient voice as part of the drug development and regulatory approval process.

"Our community faces significant loss of life each year to consequences of this rare and devastating disease," says Emily Milligan, MPH, BSF's Executive Director. "In addition to other serious and life-limiting aspects of the disease, cardiac complications such as heart failure and life-threatening arrythmias are difficult to manage and significantly alter quality and length of life for those who are affected. We believe active engagement with FDA to raise awareness of the patient perspective is critical. Absolutely no one has the ability to better communicate the impact of living with a disease, or speak to risk tolerance, than the patient or the caregiver."

“Before Barth syndrome, to my knowledge, no patient community has specifically discussed the degree of uncertainty it would accept for potential new drugs.

Post this

The passage of the 21st Century Cures Act of 2016 made considerable advances in updating FDA's regulatory review process to include the patient voice. To inform FDA and other stakeholders about the impacts of living with Barth syndrome and the needs for approved treatments, BSF hosted an externally-led Patient Focused Drug Development (EL-PFDD) meeting in 2018 – the first to be held outside the Washington DC area. Over 25% of the global known living population of people with Barth syndrome participated in the meeting. Since then, BSF has continued to focus on bringing patients' voices to the forefront of drug development decision-making processes.

Kate McCurdy, BSF's Board chair and co-founder recognizes the adversity that families with Barth syndrome face and the opportunity for BSF to have an impact. "We are tireless because we believe there are very real opportunities for us to advance research not only in Barth syndrome but also in areas that overlap with other diseases. The most important thing we can do is provide a roadmap to hope and make sure our family's voices are heard. Without treatments, we strip the potential of every child to become a brilliant and contributing young person, of every affected adult to be able to work, to get an education, to have a decent quality of life. Uncertainty is not something that we are afraid of. We live with it every day."

This most recent dialogue between the Barth syndrome community and members of various groups within the FDA (including those from the Division of Cardiology and Nephrology and the Division Rare Diseases and Medical Genetics in the Center for Drug Evaluation and Research - CDER, as well as representatives from the Center for Biologics Evaluation and Research - CBER) showcases ways in which BSF is pioneering new territory in rare disease drug development and approval. This FDA listening session, while focused on the cardiac aspects of Barth syndrome, helped demonstrate more broadly how people with rare diseases share unique attitudes toward acceptance of less certainty when considering benefits. Darryl, a young adult who suffers from Barth syndrome, who participated in the listening session, shares his perspective. "I understand that, even if a drug has gone through a clinical trial, it doesn't necessarily mean that a clinical benefit is guaranteed. I understand that there may be unknowns when the drug has only been studied in a very small number of people because my condition is so rare. I even understand that a drug might help some people feel better, but it might not help me. But I still want to try. I'll keep trying. I am steadfast in my willingness to try because I literally have no other options, and I want to live."

The emphasis on acceptance of less certainty when considering the clinical benefit of therapies was a first in FDA listening sessions, not only for Barth syndrome but for all rare diseases. Uncertainty is something FDA has long-recognized in its regulations at 21 CFR 312.80, which calls for flexibility in applying its approval standards to drugs for life-threatening and severely debilitating diseases, especially where there is no satisfactory alternative therapy. In December 2019 guidance, FDA reaffirmed that less certainty about effectiveness may be acceptable, especially in rare disease settings. "To my knowledge, before Barth syndrome, no patient community has specifically discussed the degree of uncertainty it would accept for potential new drugs. This builds on the important input this community provided at the EL-PFDD meeting, which helped describe the seriousness of Barth and its dire unmet medical need from the patient perspective. Together, this understanding of the patient experience and patients' expectations will help FDA apply its regulatory framework in a tailored and appropriately flexible way," says James Valentine, food and drug lawyer at Hyman, Phelps & McNamara, P.C.

Barth Syndrome Foundation is grateful to all the listening session participants, including the affected individuals, caregivers and bereaved parents who bravely shared their stories, as well as members of FDA who posed thoughtful questions and listened in earnest in order to better understand the perspectives of patients with the rare disease Barth syndrome.

ABOUT BARTH SYNDROME FOUNDATION (BSF)
Barth Syndrome Foundation (http://www.barthsyndrome.org) and our international affiliates comprise the only global network of families, healthcare providers, and researchers solely driven by the mission to save lives through education, advances in treatment and finding a cure for Barth syndrome. Considered a role model in rare disease advocacy, BSF has funded nearly $5.6M USD since 2002 and catalyzed over $26M USD in funding from other agencies to advance global scientific discoveries to end the suffering and loss of life from Barth syndrome. Additionally, BSF provides a lifeline to families and individuals living with Barth syndrome around the world, offering individualized support, educational conferences, a patient registry and collaborations with specialist healthcare providers to define standards of care, treatment and rapid diagnosis.

ABOUT BARTH SYNDROME
Barth syndrome is a rare, life-threatening, genetic mitochondrial disorder primarily affecting males. Affected individuals may suffer from heart failure and cardiac arrhythmia issues, muscle weakness, and infection (caused by neutropenia). Additional characteristics of the syndrome commonly include growth delay, extreme fatigue, feeding problems, impaired lipid metabolism, and cardiolipin deficiency. In some individuals affected by Barth syndrome, the symptoms can be very severe, resulting in heart transplantation, potentially lethal infections, and death.

Media Contact

Emily Milligan, Barth Syndrome Foundation, +1 (646) 937-4123, [email protected]

Twitter, Facebook

SOURCE Barth Syndrome Foundation

Related Links

http://www.barthsyndrome.org

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.